EU/3/17/1948

About

On 12 December 2017, orphan designation (EU/3/17/1948) was granted by the European Commission to Premier Research Group Limited, United Kingdom, for 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (also known as Tempol) for the treatment of familial cerebral cavernous malformation.

Key facts

Active substance
4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl
Disease / condition
Treatment of familial cerebral cavernous malformation
Date of first decision
12/12/2017
Outcome
Positive
EU designation number
EU/3/17/1948

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Premier Research Group Limited
1st Floor, Rubra 2
Mulberry Business Park
Fishponds Road
Wokingham
Berkshire RG41 2GY
United Kingdom
Tel. +44 (0)1189 364 534
E-mail: orphandrugs@premier-research.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating